1. An enhanced intracellular delivery platform based on a distant diphtheria toxin homolog that evades pre-existing antitoxin antibodies.
- Author
-
Gill, Shivneet K, Sugiman-Marangos, Seiji N, Beilhartz, Greg L, Mei, Elizabeth, Taipale, Mikko, and Melnyk, Roman A
- Abstract
Targeted intracellular delivery of therapeutic proteins remains a significant unmet challenge in biotechnology. A promising approach is to leverage the intrinsic capabilities of bacterial toxins like diphtheria toxin (DT) to deliver a potent cytotoxic enzyme into cells with an associated membrane translocation moiety. Despite showing promising clinical efficacy, widespread deployment of DT-based therapeutics is complicated by the prevalence of pre-existing antibodies in the general population arising from childhood DT toxoid vaccinations, which impact the exposure, efficacy, and safety of these potent molecules. Here, we describe the discovery and characterization of a distant DT homolog from the ancient reptile pathogen Austwickia chelonae that we have dubbed chelona toxin (ACT). We show that ACT is comparable to DT structure and function in all respects except that it is not recognized by pre-existing anti-DT antibodies circulating in human sera. Furthermore, we demonstrate that ACT delivers heterologous therapeutic cargos into target cells more efficiently than DT. Our findings highlight ACT as a promising new chassis for building next-generation immunotoxins and targeted delivery platforms with improved pharmacokinetic and pharmacodynamic properties. Synopsis: Pre-existing antibodies against diphtheria toxin (DT) from childhood vaccinations limit the efficacy and widespread use of DT-based immunotoxins. A toxin platform retaining the structural and functional features of DT but not recognized by pre-existing antibodies in human sera was developed. Distant DT homologs (ACT1 and ACT2) derived from the reptile pathogen Austwickia chelonae were found to have functional translocases and catalytic domains. ACT toxins evade recognition by pre-existing antibodies to DT in human sera, showing antibody titers below the limit of quantification. Engineered ACT-based immunotoxins retargeted to cancer-associated receptors killed receptor positive cancer cells. ACT could represent promising alternative immunotoxin platform for cancer therapy with improved pharmacokinetic and pharmacodynamic properties. Pre-existing antibodies against diphtheria toxin (DT) from childhood vaccinations limit the efficacy and widespread use of DT-based immunotoxins. A toxin platform retaining the structural and functional features of DT but not recognized by pre-existing antibodies in human sera was developed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF